MyFinsight
Home
Blog
About
Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,756K
Free Cash flow
-$20,528K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sale of fixed maturity securitie...
Loss on lease component terminat...
Depreciation
Others
Negative Cash Flow Breakdown
Acquisition of fixed maturity se...
Change in fair value of continge...
Prepaid expenses and other asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-34,550
-21,645
-19,171
-34,428
Depreciation
2,615
3,004
3,550
3,129
Non-cash operating lease expense (benefit)
406
412
427
517
Stock-based compensation
1,950
1,445
1,300
892
Impairment
-
-
0
6,763
Accretion of investments
148
211
349
507
Change in fair value of contingent liabilities
1,939
1,818
4,919
-240
Loss on lease component termination
-11,145
-
0
1,395
Deferred tax (benefit) expense
-
-
-73
-
Prepaid expenses and other assets
1,155
62
-1,321
-585
Operating lease liability
-989
-786
-1,399
-1,232
Deferred revenue
-
-
0
0
Accounts payable
1,673
-1,625
2,157
-591
Accrued expenses and other liabilities
1,158
-3,956
1,079
443
Security deposit
0
-20
-
-
Net cash used in operating activities
-19,834
-25,262
-16,077
-25,584
Acquisition of property and equipment
694
584
-139
195
Sale of property and equipment
59
-
-
-
Acquisition of fixed maturity securities, available for sale
15,967
140,691
15,599
11,023
Sale of fixed maturity securities, available for sale
34,369
28,660
37,821
35,889
Net cash provided (used in) by investing activities
17,767
-112,615
22,361
24,671
Proceeds from issuance of common stock and espp
347
202
53
0
Proceeds from pipe, net of issuance costs
-36
126,421
-
-
Net cash provided by financing activities
311
126,623
53
0
Net decrease in cash, cash equivalents, and restricted cash
-1,756
-11,254
6,337
-913
Cash, cash equivalents and restricted cash, beginning of period
53,757
65,011
58,674
61,213
Cash, cash equivalents and restricted cash, end of period
52,001
53,757
65,011
58,674
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sale of fixed
maturity securities,...
$34,369K
(-59.95%↓ Y/Y)
Proceeds from issuance of
common stock and espp
$347K
(189.17%↑ Y/Y)
Sale of property and
equipment
$59K
Net cash provided
(used in) by investing...
$17,767K
(-70.62%↓ Y/Y)
Net cash provided by
financing activities
$311K
(159.17%↑ Y/Y)
Canceled cashflow
$16,661K
Canceled cashflow
$36K
Net decrease in
cash, cash...
-$1,756K
(-8.00%↓ Y/Y)
Canceled cashflow
$18,078K
Loss on lease
component termination
-$11,145K
Depreciation
$2,615K
(-59.28%↓ Y/Y)
Stock-based compensation
$1,950K
(-58.05%↓ Y/Y)
Accounts payable
$1,673K
(41925.00%↑ Y/Y)
Accrued expenses and
other liabilities
$1,158K
(119.84%↑ Y/Y)
Non-cash operating lease
expense (benefit)
$406K
(-58.06%↓ Y/Y)
Acquisition of fixed
maturity securities,...
$15,967K
(-34.97%↓ Y/Y)
Acquisition of property and
equipment
$694K
(-12.37%↓ Y/Y)
Proceeds from pipe, net of
issuance costs
-$36K
Net cash used in
operating activities
-$19,834K
(68.12%↑ Y/Y)
Canceled cashflow
$18,947K
Net income (loss)
-$34,550K
(-178.49%↓ Y/Y)
Change in fair value of
contingent liabilities
$1,939K
(1437.24%↑ Y/Y)
Prepaid expenses and
other assets
$1,155K
(364.91%↑ Y/Y)
Operating lease liability
-$989K
(57.86%↑ Y/Y)
Accretion of investments
$148K
(-90.14%↓ Y/Y)
Buy us a coffee